Citations

Clear

35 citation(s) found for "Chan, Wing C".

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies
Lee, Jae-Woong, Chen, Zhengshan , Chan, Lai N. , Chan, Wing C. , Forman, Stephen J. , Berkel, Patrick van, Weinstock, David M. , Geng, Huimin , Luger, Selina M. , Litzow, Mark R. , Bélot, Alexandre , Uzel, Gülbû , Paietta, Elisabeth , Meffre, Eric , Müschen, Markus , Kume, Kohei , Xiao, Gang , Cosgun, Kadriye Nehir , Chen, Chun‐Wei , Pillai, Raju K. , Kwak, Larry W. , Zammarchi, Francesca , Melnick, Ari , Ngo, Vu N. , McManus, Michael T.

Mayo Clinic

Blood | October 14, 2019 | Volume: 132 | Issue: Supplement 1 | Pages: 776-776

10.1182/blood-2018-99-117553 Get It

Abstract Studying gene expression and clinical outcome data from 136 clinical trials for patients with cancer (~21,000 patients with 26 cancer types), we found CD25 as one of the strongest predictors of poor clinical outcome in patients with B-cell malignancies, but not in other cancer types. This was unexpected because CD25 is known as one of three chains of the IL2 receptor on T-cells and NK-cells. Interleukin-2 (IL2) functions as essential T-cell growth factor. IL2 signals through β- and γ-, but not α-chains (CD25) of its heterotrimeric receptor. CD25-deficiency causes lymphoproliferation and autoimmunity, however, its mechanistic role is unclear. Our experiments based on genetic mouse models and engineered patient-derived B-cell leukemia and lymphoma xenografts revealed that CD25 expressed on B-cells is not an IL2 receptor chain, but in fact binds the B-cell receptor (BCR) to regulate its activity. Suggesting IL2-independent functions, defects in CD25-/-B-cells were not replicated in IL2-deficient mice. CD25 bound the BCR but not IL2Rβ- and IL2Rγ-chains. IL2Rβ- and IL2Rγ-chains can pair with other chains to form receptors for different cytokine-ligands. However, CD25 represents the first example of a cytokine receptor chain that binds to the BCR for negative feedback regulation. Likewise, in T-cells, CD25 had a bifunctional role and either functioned as IL2 receptor chain or as negative feedback regulator of T-cell receptor signaling. CD25-function was regulated by cell-membrane translocation, which required phosphorylation of its cytoplasmic tail at S268 (see schematic, left). In a family with monogenic autoimmunity, a mutation immediately preceding S268 compromised CD25-surface translocation, which was restored by homology-directed repair of the S268 motif. CD25-interactome analyses identified PKCd as critical effector molecule downstream of CD25 to mediate B-cell selection during normal B-cell development and calibrate oncogenic BCR signaling in B-cell tumors. In B-cell malignancies, BCR-dependent survival and proliferation signals are often substituted by oncogenic BCR-mimics (e.g. BCR-ABL1, JAK2, BRAFV600E, LMP2A, CD79B mutations; see schematic, right). Accordingly, we identified CD25 surface-expression as biomarker of oncogenic BCR-signaling and predictor of poor clinical outcomes. CD25-/-B-cell leukemia failed to initiate fatal disease in transplant recipients. Owing to imbalances of oncogenic BCR-signaling and p53-checkpoint activation, CD25-/- B-cell leukemia failed to initiate fatal disease in transplant recipients. In patient-derived xenograft models of drug-resistant B-cell malignancies, treatment with a CD25-specific antibody drug-conjugate (ADCT-301) extended survival of transplant recipients or eradicated disease. These findings identified CD25 as previously unrecognized feedback regulator of oncogenic BCR-signaling and provide a rationale for therapeutic targeting of CD25 in refractory B-cell malignancies. Figure. Figure. Disclosures Forman: Mustang Therapeutics: Other: Licensing Agreement, Patents & Royalties, Research Funding. Weinstock:Genentech/Roche, Monsanto: Consultancy; Novartis: Consultancy, Research Funding; Novartis, Astra Zeneca, Abbvie, Aileron, Surface Oncology, Daiichi Sankyo: Research Funding; Novartis, Dragonfly, Travera, DxTerity, Travera: Consultancy; Travera: Equity Ownership; Astra Zeneca, JAX, Samumed, Regeneron, Sun Pharma, Prescient: Patents & Royalties. Uzel:Novartis: Research Funding.
Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry
Amador, Catalina , Greiner, Timothy C. , Heavican, Tayla B., Smith, Lynette M. , Galvis, Karen, Lone, Waseem , Bouska, Alyssa , d’Amore, Francesco, Pedersen, Martin Bjerregård , Pileri, Stefano , Rosenwald, Andreas , Ott, German , Mottok, Anja , Lim, Soon Thye , Ong, Choon Kiat , Ondrejka, Sarah L. , Song, Joo Y. , Staudt, Louis M. , Weisenburger, Dennis D. , Chan, Wing C. , Iqbal, Javeed , Song, Joo Y , Ong, Choon Kiat , Bouska, Alyssa , Amador, Catalina , Greiner, Timothy C , Smith, Lynette , Pileri, Stefano , d'Amore, Francesco , Iqbal, Javeed , Agostinelli, Claudio , Feldman, Andrew L. , Savage, Kerry J. , Leval, Laurence de , Gaulard, Philippe , Campo, Elı́as , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M. , Lone, Waseem G

Mayo Clinic

Blood | September 27, 2019 | Volume: 134 | Issue: 24 | Pages: 2159-2170

10.1182/blood.2019000779 | PMID 31562134 Get It

One-third of peripheral T-cell lymphomas are “not otherwise specified” (PTCL-NOS), but they have been subdivided into 2 subgroups based on gene expression profiling. Amador and colleagues generated an immunohistochemical algorithm that parallels the molecular separation of PTCL-NOS and provides useful prognostic information.
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
Mottok, Anja , Wright, George W. , Rosenwald, Andreas , Ott, German , Ramsower, Colleen , Braziel, Rita M., Delabie, Jan , Weisenburger, Dennis D. , Song, Joo Y. , Chan, Wing C. , Cook, James R. , Fu, Kai , Greiner, Tim O., Smeland, Erlend B., Glinsmann‐Gibson, Betty, Gascoyne, Randy D. , Staudt, Louis M. , Glinsmann-Gibson, Betty J, Steidl, Christian , Delabie, Jan , Song, Joo Y , Ramsower, Colleen A , Campo, Elı́as , Greiner, Tim, Holte, Harald , Savage, Kerry J. , Jaffe, Elaine S. , Connors, Joseph M. , Scott, David W. , Steidl, Christian , Rimsza, Lisa M. , Wright, George

Mayo Clinic

Blood | September 26, 2018 | Volume: 132 | Issue: 22 | Pages: 2401-2405

10.1182/blood-2018-05-851154 | PMID 30257882 Get It

Abstract Primary mediastinal large B-cell lymphoma (PMBCL) is recognized as a distinct entity in the World Health Organization classification. Currently, the diagnosis relies on consensus of histopathology, clinical variables, and presentation, giving rise to diagnostic inaccuracy in routine practice. Previous studies have demonstrated that PMBCL can be distinguished from subtypes of diffuse large B-cell lymphoma (DLBCL) based on gene expression signatures. However, requirement of fresh-frozen biopsy material has precluded the transfer of gene expression–based assays to the clinic. Here, we developed a robust and accurate molecular classification assay (Lymph3Cx) for the distinction of PMBCL from DLBCL subtypes based on gene expression measurements in formalin-fixed, paraffin-embedded tissue. A probabilistic model accounting for classification error, comprising 58 gene features, was trained on 68 cases of PMBCL and DLBCL. Performance of the model was subsequently evaluated in an independent validation cohort of 158 cases and showed high agreement of the Lymph3Cx molecular classification with the clinicopathological diagnosis of an expert panel (frank misclassification rate, 3.8%). Furthermore, we demonstrate reproducibility of the assay with 100% concordance of subtype assignments at 2 independent laboratories. Future studies will determine Lymph3Cx’s utility for routine diagnostic purposes and therapeutic decision making.
A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
Azad, Nilofer S. , Dy, Grace K. , Gallagher, Denise , Brennen, Caden, Cutler, David L. , Kramer, Douglas, Kwan, Rudolf, Fetterly, Gerald J., Adjei, Alex A. , Jimeno, Antonio , Wee, Wen , Lam, Elaine T. , Diamond, Jennifer R. , Opyrchal, Mateusz , Chan, Wing‐Kai

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2526-2526

10.1200/jco.2018.36.15_suppl.2526 Get It

Autologous Transplantation for Aggressive Non-Hodgkin’s Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease
Chan, Wing C. , Nichols, Craig R. , Loh, Kevin K., Inwards, David J. , Rifkin, Robert M. , Bierman, Philip J., Lynch, James C. , Weisenburger, Dennis D. , Kessinger, Anne, Vose, Julie M. , Sharp, Graham , Armitage, Jamés O.

Mayo Clinic

Journal of Clinical Oncology | July 27, 2002 | Volume: 20 | Issue: 9 | Pages: 2344-2352

10.1200/jco.2002.09.138 | PMID 11981006 Get It

PURPOSE: To determine whether the source of autologous hematopoietic stem cells altered the clinical outcomes of patients undergoing high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) for aggressive non-Hodgkin’s lymphoma (NHL). PATIENTS AND METHODS: Of 105 high-risk, persistent, or relapsed NHL patients slated for an autologous HSCT entered onto this trial, 93 eligible patients were randomized to receive cytokine-naive autologous bone marrow transplantation (ABMT) (n = 46) or mobilized peripheral-blood stem-cell transplantation (PBSCT) (n = 47). All patients received carmustine, etoposide, cytarabine, and cyclophosphamide as the conditioning regimen. PBSCT patients also received identical mobilization with granulocyte colony-stimulating factor (G-CSF) 10 μg/kg/d, and both groups received G-CSF 5 μg/kg/d after the infusion of the stem-cell product until neutrophil engraftment. RESULTS: PBSCT patients had significantly faster engraftment of all cell lineages: median time to absolute neutrophil count ≥ 500/μL, 10 days versus 13 days on the ABMT arm; median time to platelet count greater than 20,000/μL untransfused, 11 days versus 15 days on the ABMT arm; and median time to RBC transfusion independence, 8 days versus 16 days on the ABMT arm. The complete response rate was 72% for PBSCT and 54% for ABMT. The death rate before posttransplant day 100 was 2% on the ABMT arm and 6% on PBSCT arm. Event-free survival was 37% for PBSCT and 37% for ABMT. However, overall survival for PBSCT was 61% compared with 43% for ABMT. CONCLUSION: Patients with aggressive NHL receiving HSCT randomized to PBSCT demonstrated improved neutrophil engraftment and platelet and RBC transfusion independence. The complete response rate and EFS were not statistically different by randomization arm. Patients whose harvests were positive for minimal residual disease by molecular analysis had poorer EFS.